# Microvascular Blood Flow in Sickle Cell Anemia

> **NCT01566890** · NA · COMPLETED · sponsor: **Versiti Blood Health** · enrollment: 91 (actual)

## Conditions studied

- Sickle Cell Disease
- Sickle Cell Anemia

## Interventions

- **DRUG:** regadenoson infusion with contrast-enhanced ultrasound
- **PROCEDURE:** contrast-enhanced ultrasound
- **PROCEDURE:** contrast-enhanced ultrasound
- **PROCEDURE:** contrast-enhanced ultrasound
- **PROCEDURE:** contrast-enhanced ultrasound

## Key facts

- **NCT ID:** NCT01566890
- **Lead sponsor:** Versiti Blood Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2019-07-05
- **Final completion:** 2020-11-16
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-06-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01566890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01566890, "Microvascular Blood Flow in Sickle Cell Anemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01566890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*